RNA loading is done via either proprietary exogenous or endogenous loading methods, enabling Evox to work across both natural and non-natural oligonucleotides. Solving the non-hepatic delivery challenge of nucleic acid-based drugs – such as siRNAs, anti-sense or even gene editing modalities – is a core mission for Evox and tissue-targeted exosomes represent a very promising technology to achieve the delivery of RNA therapeutics.